Back to Search
Start Over
Effectiveness and safety of adalimumab in Japanese patients with rheumatoid arthritis: retrospective analyses of data collected during the first year of adalimumab treatment in routine clinical practice (HARMONY study).
- Source :
-
Modern rheumatology [Mod Rheumatol] 2012 Jun; Vol. 22 (3), pp. 327-38. Date of Electronic Publication: 2011 Sep 07. - Publication Year :
- 2012
-
Abstract
- We retrospectively investigated the ability of adalimumab (ADA) to reduce disease activity, improve physical function, and retard the progression of structural damage in 167 patients with rheumatoid arthritis. Clinical and functional outcomes were compared between patients with or without prior biologic treatment and those with or without concomitant methotrexate (MTX) treatment. At week 52, 38.3% achieved clinical remission: 42.4 and 28.6% of patients achieved remission in those without and with previous biologics, respectively, while 42.7 and 12.5% of patients achieved remission in those with and without concomitant MTX, respectively. ADA treatment significantly reduced the rate of radiographic progression from 27.1 ± 46.0 (median 13.6; 25th-75th percentiles 8.3 to 28.9) at baseline to 0.8 ± 5.0 (median 0.0; 25th-75th percentiles -0.9 to 2.0) at week 52 (P < 0.0001). Radiographic progression was absent in 59.8% of patients. Sixty adverse events (34.21/100 patient-years) were reported, 16 of which were serious (9.12/100 patient-years). ADA therapy is highly effective for reducing disease activity, improving physical function, and limiting radiographic progression. It is generally safe and well tolerated by Japanese RA patients in routine clinical practice.
- Subjects :
- Adalimumab
Adult
Aged
Antibodies, Monoclonal, Humanized adverse effects
Antirheumatic Agents adverse effects
Arthritis, Rheumatoid diagnostic imaging
Asian People
Disease Progression
Drug Therapy, Combination
Female
Humans
Japan
Male
Methotrexate therapeutic use
Middle Aged
Radiography
Remission Induction
Retrospective Studies
Treatment Outcome
Antibodies, Monoclonal, Humanized therapeutic use
Antirheumatic Agents therapeutic use
Arthritis, Rheumatoid drug therapy
Tumor Necrosis Factor-alpha antagonists & inhibitors
Subjects
Details
- Language :
- English
- ISSN :
- 1439-7609
- Volume :
- 22
- Issue :
- 3
- Database :
- MEDLINE
- Journal :
- Modern rheumatology
- Publication Type :
- Academic Journal
- Accession number :
- 21898074
- Full Text :
- https://doi.org/10.1007/s10165-011-0516-6